Promotie

Promotie

Promotie

Promotie

Can light-activatable ruthenium compounds be used as a more selective anticancer treatment?

The overall aim of CAM-PaC is to contribute to solving the socioeconomic and health challenges of PDAC by an integrative and systematic functional analysis of pancreatic cancer candidate genes. CAM-PaC will develop novel cellular and animal models, as well as novel strategies to analyse and integrate…

A month ago it was Marc Baggelaar, and now Hans Kistemaker too has obtained his PhD cum laude at the Leiden Institute for Chemistry (LIC). ‘He has made ground-breaking contributions to the world of protein modification,’ says PhD supervisor Gijs van der Marel. Kistemaker obtained his PhD on 11 May…

Promotor: Prof.dr. H.P. Spaink Co-promotor: Dr. B.E. Snaar

Is it possible for sugar patterns on cells to activate the immune system to combat cancer?

For effective cancer immunotherapy by vaccination, co-delivery of tumour antigens and adjuvants to dendritic cells and subsequent activation of antigen-specific cytotoxic T cells (CTLs) is crucial. In this study, a synthetic long peptide (SLP) harbouring the model CTL epitope SIINFEKL was encapsulated…

Key publications of the Cancer Drug Target Discovery group

In the research programme Drug Discovery & Safety, we are interested in the efficacy and safety of new drugs and novel means to decipher these aspects. Hence, we employ advanced imaging and high-throughput screening techniques next to computational approaches such as chem- and bioinformatics.

Researchers at Leiden University have demonstrated that tumours can apply mechanical means to attract the blood vessels they need to be able to grow. The team published this discovery on 2 March in Nature Scientific Reports.

Promotie

Chemotherapy that does nothing until you irradiate it with light. Sylvestre Bonnet receives a Vici grant of 1.5 million euros for the development of this treatment. The Leiden chemist wants to build a new molecule to fight tumours that are at the time still difficult to treat.

Leiden has a long history in the treatment of blood cell cancer. Research to find better therapies never stands still. One of the potential treatments currently being worked on is a ‘living medicine’.

We are interested in the efficacy and safety of new drugs and novel means to decipher these aspects. Hence, we employ advanced imaging and high-throughput screening techniques next to computational approaches such as chem- and bioinformatics.

Promotie

Promotie

Promotie

Promotie

Promotie

Promotie

Treatment and care for cancer patients is becoming increasingly advanced. For example, surgeons can now perform operations with much greater precision, and therapeutic vaccines are being developed to prompt the patient’s immune system to fight cancer. Work is also being done on better early diagnostics,…

With cancer, the immune system is a double-edged sword: it can attack tumour cells, but can also help them grow and spread. It is a question of harnessing it. This is what Professor Karin de Visser argued in her inaugural lecture on 15 November 2019.

How can new compounds relieve cancer patients of severe side effects?

Research groups in the Biological & Soft Matter Programme unravel mechanisms in biological processes and develop novel bio-inspired soft materials.

Is it possible to successfully design self-assembling nano-scale protein skeletons for use as a vaccine platform?

How can we find novel natural products from Actinomycetes that act as growth modulators on mammalian cells? Can we harvest and develop the potential of these novel compounds for industrial and medical biotechnology?

An overview of the research at the Cancer Dug Target Discovery group.

How does the extracellular matrix coordinate endothelial cell behavior during angiogenesis, and how do metabolic waste-products and matrix-degrading enzymes produced by the tumour modify the extracellular matrix so as the change the cellular coordination?

Strengthening a cancer patient's own immune system so that the body itself can better destroy cancer cells. This is at the heart of immunotherapy, the most promising progress in cancer treatment in recent years. In order to drive this development further, the Netherlands Cancer Institute-Antoni van…

The Leiden Institute of Physics has been awarded three out of twelve available grants from the FOM Projectruimte. Principal Investigators Milan Allan, Stefan Semrau and Carlo Beenakker all receive around 400,000 euro for their research.

Lezing

Lezing

More and more medicines are becoming available that target a tumour’s specific traits. The use of chemotherapy is continually undergoing improvement.

Promotie

Promotie

Promotie

Promotie

Promotie

Promotie

Promotie

Promotie

Promotie

Promotie

Promotie

Promotie